- Home
- IMCC vs RDHL Comparison
IMCC vs RDHL Comparison
Compare IMCC & RDHL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | IMCC | RDHL |
|---|---|---|
| Founded | 1980 | 2009 |
| Country | Israel | Israel |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.0M | 3.3M |
| IPO Year | 2019 | 2012 |
Fundamental Metrics
Financial Performance| Metric | IMCC | RDHL |
|---|---|---|
| Price | $4.33 | $0.57 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 348.9K | ★ 2.5M |
| Earning Date | 05-08-2026 | 04-27-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $63.88 | $381.91 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.09 | $0.54 |
| 52 Week High | $4.15 | $2.79 |
Technical Indicators
Market Signals| Indicator | IMCC | RDHL |
|---|---|---|
| Relative Strength Index (RSI) | 76.94 | 40.80 |
| Support Level | $0.27 | N/A |
| Resistance Level | N/A | $0.85 |
| Average True Range (ATR) | 0.67 | 0.11 |
| MACD | 0.05 | -0.02 |
| Stochastic Oscillator | 38.73 | 2.77 |
Price Performance
Historical ComparisonAbout IMCC IM Cannabis Corp.
IM Cannabis Corp is a Canada-based international medical cannabis company. It operates in the field of medical cannabis, through Focus Medical Herbs Ltd. (Focus), which holds a cultivation license to breed, grow, and supply medical cannabis products The majority of its revenues are generated from sales of medical cannabis products to customers in Israel. The remaining revenues are generated from sales of medical cannabis, as well as other products, to customers in Germany. Geographically, the majority revenue is generated from Germany, and also has its presence in Israel.
About RDHL Redhill Biopharma Ltd.
RedHill Biopharma Ltd is a specialty biopharmaceutical company mainly focused on the U.S. development and commercialization of drugs for GI diseases, infectious diseases, and oncology. The Company is mainly focused on the advancement of its development pipeline of clinical-stage therapeutic candidates and also commercializes its GI-related product, Talicia (omeprazole, amoxicillin, and rifabutin) in the U.S. Its therapeutic candidates include opaganib, RHB-204, RHB-104, RHB-102 (Bekinda), and RHB-107.